About Us » Management Team

Management Team

Dr. Brian MIN


  • B.A. from University of California, Berkeley
  • Ph.D. from University of California, Los Angeles
  • 20+ years of experience on biologics development and manufacturing
  • 10+ years experience of antibody discovery in Amgen
  • Experience from target identification/validation to market approval of biologics
  • Played a key role in development of 2 marketed novel biologics
  • Financial impact analysis of drug development and commercialization
  • Experience in IMPD and CTD preparation as well as interaction with regulatory agencies (EMA, FDA, etc.).
  • Led development and manufacturing of all biosimilars in Samsung Bioepis; Scale-up experience to 15,000L bioreactor
  • 4 biosimilar products marketed in US, EU and Korea, 2 entered clinical trial phase III, and 2 entered clinical phase I
  • Core team member that led formation for Samsung Bio companies through joint venture formations
  • Mr. Daniel WANG

    Head of Operation

    • 10+ years' experience in team management, business management, and operations management
    • 14+ years' experience in protein expression, biologics development
    • 2 products entered clinical trial, 3 products entered IND filing
  • Mr. Fredy CHU

    Head of Quality

    • M.S., Analytical Chemistry, Iowa State University
    • 30+ years in pharma/biologics quality management
    • Baxter, Collagen, ChemPartner, PharmaEssentia, Kanghong, Xoma, Fibrogen
    • Responsible for FDA, EMA PAI approvals in US and Asia
    • Multiple successful GMP facility validation in US and Asia
    • Experienced in QA/QC management of multi-site global pharma/biotech
    • Seasoned quality practitioner in drug development, clinical and commercial operations in US, Asia, and EU
  • Dr. Cuiying Shao

    Vice President of R&D

    • Dr. Cuiying Shao has more than 20 years experience on biologics drug R&D. She set up Roche Glycart China antibody drug discovery group in 2007 and the team delivered antibody drug leads for multiple projects against various targets for different diseases areas of oncology, neuroscience, ophthalmology, and immunology. She has been Served as Senior Director and Site Head of Roche Large Molecule Research in Roche Shanghai Innovation Center, Head of Antibody Protein Cellular Structure Science (APCSS) of GSK China R&D Center, Vice President of Qilu Pharmaceutical R&D Shanghai Center, Vice President of GenScript Strategic Research, CEO of Tuojie Biotechnology (Shanghai), a subsidiary biotech of Jiangsu Hengrui Medicine. Now she is the R&D Vice President of GenScript Probio.
    • Dr Shao obtained her Ph.D. in Molecular Biology and continued the postdoctoral research in bioengineering at the University of Aberdeen and University of Cambridge.
  • Dr. Lifeng He

    Head of Global Marketing and China BD

    • Ph.D and Postdoc in Molecular Pharmacology from the Albert Einstein College of Medicine
    • ~20 years of commercial experience in US and China biotech industry
    • More than 10 years of commercial leadership experience in CDMO and IVD companies
    • Led marketing campaigns, new product launch and BD efforts, and served as GM China for a leading US IVD company
    • WuXi Biologics, MabPlex, Covance, Cepheid
  • Dr. Sean LIOUR

    Head of PM & RA

    • Ph.D from Virginia Commonwealth University
    • 10+ years' experience in biologics project management
    • Fountain Biopharma, development of a novel therapeutic antibody project, IND filing and phase I study
    • 2016 joined Shanghai Henlius Biotech, participated in the development and IND/NDA filing of novel antibody drug-conjugate (ADC), novel antibodies and biosimilars.
  • Mr. Kenneth Lee

    Head of BD & Commercial Excellence, Americas

    • B.S. in Molecular Cell Biology from University of California, Berkeley
    • MBA from INSEAD (France)/ Wharton (U.Penn)
    • 14 years of experience in biologics discovery, development, manufacturing, and commercialization
      • 10 years of experience in biologics/ biosimilar business development, launch, marketing, and sales
      • 4 years of experience in medicinal chemistry, bioanalytical testing, and quality assurance at Gilead Sciences, Elan Pharmaceuticals, and BioMarin Pharmaceuticals.
    • Led global launch, partnership management, and commercialization efforts at Samsung Bioepis for its world-leading biosimilars (over $1B sales globally)
    • Led global licensing deals for biologics/ biosimilars with #1 pharmas in Japan, Russia, Turkey
  • Mr. Kun YIN

    Head of Europe and APAC BD

    • B.S. from Nanjing University, in Biology Science
    • MBA from Nanjing University, Business School
    • 14 years’ experience in marketing management
    • 6+ years’ experience in sales management and business development
    • Led multiple out-licensing and co-development projects